Yes the price per indication would be different as the number of cycles can be different, but it is rare outside of sarcoma to go past 4 cycles these days because of the cardiotoxicity risk.
The estimate in the Triangle report is pretty conservative - to give you an example, G1 Therapeutics' Cosela has a list price of $US32K per chemo cycle and it provides no anticancer efficacy, just some (limited) protection from myleosupression.
Yes the price per indication would be different as the number of...
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.30 |
Change
-0.010(0.76%) |
Mkt cap ! $215.6M | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.31 | $1.23 | $212.1K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5201 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 9799 | 2 |
View Market Depth
| Last trade - 16.10pm 29/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.28 |
Change
-0.010 ( 1.17 %) |
||||
| Open | High | Low | Volume | ||
| $1.30 | $1.31 | $1.23 | 17594 | ||
| Last updated 15.52pm 29/04/2024 ? | |||||
| RAC (ASX) Chart |